TNXP Tonix Pharmaceuticals Holdi...

Nasdaq tonixpharma.com


$ 17.80 $ -0.01 (-0.06 %)    

Wednesday, 12-Nov-2025 15:04:09 EST
QQQ $ 619.76 $ -5.02 (-0.8 %)
DIA $ 482.86 $ 2.30 (0.48 %)
SPY $ 682.59 $ -2.18 (-0.32 %)
TLT $ 90.13 $ 0.18 (0.19 %)
GLD $ 386.15 $ 6.01 (1.58 %)
$ 17.53
$ 17.69
$ 17.80 x 300
$ 17.86 x 100
$ 17.66 - $ 18.31
$ 6.76 - $ 130.00
513,714
na
206.44M
$ 2.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-18-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-16-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 04-01-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 03-13-2023 12-31-2022 10-K
13 11-07-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-14-2022 12-31-2021 10-K
17 11-08-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-15-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-12-2020 03-31-2020 10-Q
24 03-24-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-12-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-09-2018 09-30-2018 10-Q
30 08-13-2018 06-30-2018 10-Q
31 05-11-2018 03-31-2018 10-Q
32 03-09-2018 12-31-2017 10-K
33 11-06-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 05-12-2017 03-31-2017 10-Q
36 04-13-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 03-03-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tonix-pharmaceuticals-q3-eps-359-misses-358-estimate-sales-3290m-beat-3100m-estimate

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(3.59) per share which missed the analyst consensus estimate ...

 tonix-teams-up-with-mass-general-to-test-new-antibody-for-kidney-transplant-patients

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial bi...

 tonix-pharma-presents-data-on-tonmya-which-was-investigated-as-tnx-102-sl-at-2025-acr-convergence

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment wa...

 tonix-starts-first-patient-dosing-in-study-testing-oxytocin-therapy-for-rare-disorder

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated biotechnology ...

 tonix-pharmaceuticals-ceo-highlights-tnx-1500-progress-and-anti-cd154-therapy-in-organ-transplantation-at-japan-conference

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated biotechnology ...

 tonix-pharma-plans-to-progress-tnx-2900-program-for-treatment-of-pws-into-phase-2-clinical-trial

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to ...

 tonix-pharmaceuticals-completes-type-b-pre-ind-meeting-with-fda-for-tnx-102-sl-for-treatment-of-major-depressive-disorder

Tonix anticipates filing the IND application in the fourth quarter of 2025TNX-102 SL is a potential first-in-class treatment fo...

 tonix-pharmaceuticals-announces-in-licensing-of-tnx-4800-monoclonal-antibody-for-annual-lyme-disease-prevention-across-us-endemic-regions

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: ...

 tonix-presents-clinical-data-on-tonmya-for-treatment-of-fibromyalgia-at-painweek-conference-2025-phase-3-data-support-q4-launch-following-painweek-showcase

Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for...

 tonix-pharmas-drug-gets-fda-nod-for-chronic-pain-condition-first-new-therapy-in-over-15-years

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION